Key terms
About QDEL
QuidelOrtho Corp. operates as a vitro diagnostics company. It is focused on developing and manufacturing diagnostic products. The company was founded on May 27, 2022 and is headquartered in San Diego, CA.
Sector
Industry
Employees
Founded
Website
Key stock statistics
1-day range
52-week range
Market cap
P/E ratio
Next earnings date
Dividend yield
Ex-dividend date
Dividend pay date
Key terms
Ad Feedback
Smart score
Latest QDEL news
Mar 11
10:10pm ET
Analysts Offer Insights on Healthcare Companies: QuidelOrtho (QDEL), OrthoPediatrics (KIDS) and RegenXBio (RGNX)
Mar 08
2:21pm ET
Buy/Sell: Wall Street’s top 10 stock calls this week
Mar 06
4:42pm ET
QuidelOrtho receives Health Canada Approval for Quidel Triage PLGF Test
Mar 04
9:44am ET
DoorDash, Lyft upgraded: Wall Street’s top analyst calls
Mar 04
5:02am ET
QuidelOrtho downgraded to Sell from Neutral at UBS
Feb 21
10:01am ET
QuidelOrtho ‘vulnerable to an approach,’ says Gordon Haskett
Feb 21
8:46am ET
Craig-Hallum downgrades QuidelOrtho (QDEL) to a Hold
Feb 21
7:59am ET
QuidelOrtho will postpone its previously announced Investor Day
Feb 21
7:45am ET
QuidelOrtho Announces Executive Leadership Restructuring
Feb 21
7:43am ET
QuidelOrtho announces termination of President and CEO Douglas Bryant
Feb 16
2:22pm ET
Buy/Sell: Wall Street’s top 10 stock calls this week
Feb 16
7:12am ET
QuidelOrtho Updates 2024 Financial Guidance and Outcomes
Feb 14
10:05am ET
Airbnb downgraded, Citi upgraded: Wall Street’s top analyst calls
Feb 14
10:05am ET
Airbnb downgraded, Citi upgraded: Wall Street’s top analyst calls
Feb 14
8:42am ET
Craig-Hallum downgrades QuidelOrtho to Hold, cuts price target to $50
Feb 14
7:51am ET
QuidelOrtho price target lowered to $81 from $130 at RBC Capital
Feb 14
7:23am ET
William Blair downgrades QuidelOrtho with shares in ‘penalty box’
Feb 14
6:51am ET
QuidelOrtho downgraded to Outperform from Strong Buy at Raymond James
Feb 14
6:44am ET
QuidelOrtho downgraded to Market Perform from Outperform at William Blair
Feb 14
5:43am ET
QuidelOrtho downgraded to Underweight from Neutral at JPMorgan
Feb 13
5:34pm ET
QuidelOrtho falls 30% to $46.50 after Q4 results, FY24 guidance miss estimates
Feb 13
5:29pm ET
QuidelOrtho says Q4 results ‘not as expected’
Feb 13
5:07pm ET
QuidelOrtho expects FY24 Labs business growth mid-to-high single digits
Feb 13
4:13pm ET
QuidelOrtho sees FY24 adjusted EPS $2.40-$3.07, consensus $5.07
Feb 13
4:09pm ET
QuidelOrtho reports Q4 EPS $1.17, consensus $2.05
Feb 12
8:29am ET
QuidelOrtho (QDEL) Receives a Buy from Craig-Hallum
Jan 26
8:46pm ET
RBC Capital Sticks to Their Buy Rating for QuidelOrtho (QDEL)
Jan 08
12:40pm ET
QuidelOrtho: Will endeavor to preannounce ‘when it makes sense’
Dec 21
8:46am ET
QuidelOrtho (QDEL) Gets a Buy from Craig-Hallum
Dec 21
7:02am ET
Analysts Conflicted on These Healthcare Names: BioMarin Pharmaceutical (BMRN), QuidelOrtho (QDEL) and Immunovant (IMVT)
Dec 20
4:06pm ET
QuidelOrtho receives 510k clearance for Savanna PCR, HSV
No recent news articles are available for QDEL
Yesterday
4:07pm ET
QDEL LOSS: ROSEN, GLOBAL INVESTOR COUNSEL, Encourages QuidelOrtho Corporation Investors to Inquire About Securities Class Action Investigation - QDEL
Mar 22
5:33pm ET
ROSEN, TOP RANKED INVESTOR COUNSEL, Encourages QuidelOrtho Corporation Investors to Inquire About Securities Class Action Investigation - QDEL
Mar 20
4:40pm ET
QDEL LOSS ALERT: ROSEN, A GLOBALLY RECOGNIZED LAW FIRM, Encourages QuidelOrtho Corporation Investors to Inquire About Securities Class Action Investigation - QDEL
Mar 16
11:41am ET
ROSEN, A LEADING INVESTOR RIGHTS LAW FIRM, Encourages QuidelOrtho Corporation Investors to Inquire About Securities Class Action Investigation - QDEL
Mar 15
11:35am ET
ROSEN, SKILLED INVESTOR COUNSEL, Encourages QuidelOrtho Corporation Investors to Inquire About Securities Class Action Investigation - QDEL
QDEL Financials
Key terms
Ad Feedback
QDEL Forecasts
analyst rating
- buy
- hold
- sell
1-year stock price forecast
QDEL Competitors
$ Market cap
P/E ratio
$ Price
1d change
52-week range